EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary

September 13, 2021

Borsa Italiana IT Health Care Health Care Equipment and Supplies earnings 59 min

Earnings Call Speaker Segments

Bianca Fersini-Mastelloni

operator
#1

Good afternoon or good morning, everyone, and welcome to the conference call on EL.En's First Half Year Financial Results of 2021. This call is being recorded today. <<operator_script>>. Joining me are Andrea Cangioli, Managing Director of El.En, and Enrico Romagnoli, El.En's Chief Financial Officer and Investor relator. Before we start, please be aware that management will make remarks on this conference call concerning your expectations, plans and prospects, as well as forward-looking statements. Some statements on this call — including those addressing the company's beliefs, plans, objectives, estimates or expectations regarding possible future results or events — are forward-looking statements. Forward-looking statements carry known or unknown risks, including general, economic and business conditions and conditions in the industry we operate in, and to maybe affecting should our caption prove out to be inaccurate. As a result, no forward-looking statements can be guaranteed, and actual future results, performance or achievements may differ materially from those expressed or implied by such forward-looking statements. The company undertakes no obligation regarding the content nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof. At this time, I want to turn the call over to Andrea Cangioli. Please go ahead, Andrea.

Andrea Cangioli

executive
#2

Thanks, Bianca. Many thanks. Good afternoon, everyone, and I appreciate your joining this conference call. Together with Enrico Romagnoli, we'll go through and comment on the El.En. Group's financial results for the first 6 months of 2021. As we announced last Friday through our press release following the Board of Directors meeting, the financial results came in very strong. Steady growth and solid profitability have been El.En's calling card in recent years. We have consistently shared with you our ambition to keep running along our growth path for several years, grounded in the growth expectation of our markets and in our efforts and investments aimed at building an organization able to seize market opportunities, and to create new opportunities through continuous innovation of our product range. With EUR 273 million in sales, an EBIT margin above 11%, and net profit exceeding EUR 20 million for the 6 months, we are therefore very pleased not only with the record results themselves, but also with how these results represent our plans coming to fruition. They rest on our long-term planning, with infrastructural investments and the yearly expense aimed at progressively improving our capabilities in research and development, in clinical studies, in marketing and in regulatory, just to name some of the areas and functions that were deeply strengthened in recent years.

Andrea Cangioli

executive
#3

The 2021 results aren't attributable to any single product, any single customer, or any single market. Instead, they're broad-based across the capabilities that the Group's various functions achieved, and the knowledge we actively cultivated and made strategic over the years, which lets us keep generating business opportunities. Meanwhile, our market recognition is growing broader and more solid. In the medical business, our brands DEKA, Quanta, Asclepion, Asa and Renaissance are no longer, and not only, viewed as the brands of a smart, innovative organization challenging the market leaders — they are now a stable and reliable reference for our customers and a benchmark for our competitors across several application segments. In the industrial business too, Cutlite and Penta are today recognized for meaningful market recognition in Europe and in China, respectively. In China, we've had a presence in the ship mental cutting business for roughly 15 years now. And the Penta brand is recognized as 1 of the leaders, with its hybrid Euro-Chinese technology offer. In the very last year alone, Cutlite gained recognition and size in Italy and Europe that are making it an actual player in a market dominated by giants — a market where, 5 years ago, our presence was negligible.

Andrea Cangioli

executive
#4

If we turn to the specifics of the financial results, comparing them with the first semester of 2020 isn't particularly meaningful this time around. During the opening months of last year, the pandemic hit us hard. Our industrial market business in China was shut down from mid-January through late March in Wenzhou, and until April in Wuhan. In Italy, industrial operations had to be suspended in March and April. And demand from medical-linked systems around the world fell off sharply at the end of March. A more useful approach is to set the current results against the first half of 2019, citing the average growth the Group delivered in the last semester under pre-pandemic conditions — in a normal environment, so to speak. For the first 6 months, average 2019–2021 growth came to 20.9% on a consolidated basis, and 20.4%, 14.4% and 29.1% respectively for the medical and industrial sectors. What these figures show is that across the last 2 years, notwithstanding the revenue decline during the acute phase of the pandemic, our growth remained steady, robust and considerably higher than the growth anticipated in our reference markets. The medical business owed its success primarily to aesthetics, where demand for our hair removal, body contouring, tattoo removal and rejuvenation solutions produced solid growth.

Andrea Cangioli

executive
#5

Our publicly reporting peers posted strong top-line results. In some application segments—hair removal in particular—we don't believe we picked up share. COVID hit our surgical application harder and for a longer stretch, and that business is recovering more slowly, system sales especially. Incidentally, the industrial side grew at double the rate of medical, and the revenue split between our 2 sectors is now nearing balance. The main drivers were traction in the ship metal cutting business in China and also in Italy. Market size keeps expanding thanks to technology improvements, which boost productivity and effectiveness of our systems both in their traditional fields and in additional applications that improved system performance is opening up and making affordable or simply feasible. We have made and continue to carry out large infrastructure investments to fit our production capacity in China and Italy to the larger market. This is a very large investment, totaling today EUR 30 million spent on new plants, roughly EUR 70.5 million in China and EUR 12.5 million in cutting for Cutlite Penta.

Andrea Cangioli

executive
#6

Like the results we're seeing, the transition out of the most acute phase of the pandemic is being accompanied by demand levels that are holding up and are sustained across all or nearly all of our businesses. Is this a rebound? Is it being driven by the optimism connected to the expansive policies that a number of countries set out last spring and are promising to maintain over the coming year? That's very difficult to determine. What we observe is extremely strong demand for our products, more robust than what we had modeled. We told you how we anticipated strong growth and how we expected the pandemic to be a parenthesis after which growth would reappear. In fact, current sales and order bookings volumes place us ahead of where we had planned to be at this point, in the planning we did before the pandemic began. Yet the pandemic remains present, with the unpredictability of its effects, not just regarding how the infection spreads and its mortality, but also regarding the complicated demands placed on the markets. The clearest negative effect we are currently encountering is the strain on the supply chain, which suffers from a severe shortage of certain materials, spanning from electronic components to metals such as aluminum and copper.

Andrea Cangioli

executive
#7

What’s really hitting us is uncertainty around delivery terms for some supply, price hikes on a number of components, and the need to raise our inventory so we can cover longer lead times on supply. A few remarks about our cash position, which is getting stronger thanks to higher profitability that is covering the financial needs created by growth in investments. It’s worth recalling now that following the 2020 suspension, El.En. resumed paying a dividend to shareholders in May 2021. Then, at the start of the summer, we carried out our second 1 to 4 share split. The first occurred 5 years ago, in 2016. The aim is to keep our share price within what appears to be a more attractive range of EUR 10 to EUR 40. In addition, over the past weeks, our market cap went above EUR 1 billion for the first time — a remarkable milestone. And we hope it becomes another enabler of investor attraction, steadily moving the company toward the mid-cap area. With that and my general introduction done, please, Enrico, go ahead with your part of the presentation.

Enrico Romagnoli

executive
#8

Thank you. Thanks, Andrea. As I typically do, I'll walk you through some specifics from our most recent financials. During the first half of 2021, carrying on from where 2020 ended, the Group's growth trend persisted following the pause caused by COVID's impact. On this slide, as you can see, we made a comparison not just against 2020 but, as Andrea already mentioned, we also did 2021 versus 2019. In H1, turnover rose 68% and came to EUR 274 million. Gross margin was EUR 99.9 million, up 66.9% versus the first half of last year, driven by the substantial rise in turnover. The gross margin percentage dipped slightly, yet it actually improved in both the medical and industrial sectors. The overall decline stems from industrial sales carrying more weight, and those structurally carry a lower margin than medical. At June, Medical's gross margin was 44% while Industrial's was 27%. Operating costs were EUR 20.8 million, higher than June 2020, though their impact on turnover fell sharply, going from 9.9% at June 2020 to 7.6% at June 2021.

Enrico Romagnoli

executive
#9

When you look at this cost aggregate, it's significant — compare it with 2019, when the total amount was higher than in 2021. Within this cost aggregate, we benefit from lower commercial expenses, and we had significant savings on international travel and on trade fair and congress activities, which represent a significant cost, particularly in the medical sector. The only trade fairs we were able to attend in this period were held in China for the metal laser cutting sector, in Japan for beauty treatment sector equipment, in Italy and Europe and Dubai for specialized congresses of various medical disciplines. Participation in important and numerous events is expected in the coming months, but it will still take a long time before these activities return to the pre-COVID intensity. Staff costs equal to EUR 40 million are up compared to the EUR 29.3 million of June 2020, but with a lower impact on turnover, decreasing from 18% in 2020 to 14.6% on June 2021, and lower than 2019, too. On June 2020, we had more than 1,800 staff. EBITDA was EUR 39.1 million, almost 3x debt 2020 and double than 2019. <<inaudible>> Sales increased at 14.3% compared to the 8.9% of last year. Amortization and other approvals showed a market — is growing from EUR 5.2 million on June 2020 to EUR 8.3 million on June 2021, while their incidence on turnover remains substantially unchanged at 3%.

Enrico Romagnoli

executive
#10

The biggest driver was a boost in the warranty provision, reflecting higher sales volume along with a somewhat longer warranty period. Across H1 2021, fixed cost, operating cost, staff cost and depreciation together rose by nearly 56%, yet their effect on sales fell from 35% -- 31% down to 25%. Because gross margin improved and the drag from fixed costs shrank, the operating result comes out positive at close to EUR 31 million — a sharp gain over the EUR 9.3 million posted in the first half of 2020 — with its share of turnover climbing to 11.3% from 5.7% in the same period a year earlier, and also above 2019, when that figure stood at 8.9%. Pretax was <<inaudible>>, helped by a favorable ForEx effect driven mainly by the U.S. dollar, which strengthened versus the euro during the period. Net income reached EUR 22.4 million, against EUR 6.4 million in H1 of last year. The net financial position grew by roughly EUR 50 million over the period, moving from EUR 64.2 million at December 2020 to EUR 78.8 million at June 2021. As required by the European Securities and Market Authority and adopted by Conso ahead of the June 2021 financials, the net financial position must now include long-term payables, even where these do not relate to financial liabilities.

Enrico Romagnoli

executive
#11

The primary long-term debt is owed to the former minority shareholders of Penta Laser Wenzhou: RMB 40 million, roughly EUR 5 million, payable under an earnout clause contained in the 2020 sales contract should Penta Laser Wenzhou go public within 5 years of the purchase date. Consistent with this new requirement, we are restating our net financial position as of the end of 2021. CapEx over the first 6 months came to EUR 11 million, versus EUR 13 million for the full year 2020. The biggest investment was Cutlite Penta's new building in Prato at EUR 5 million, bought outright rather than leased. Cash from operating activity covered the combination of the capital increase—logical at this stage of fast growth—the items stemming from <<inaudible>>, and the dividend payments to El.En and the subsidiaries that resumed after a 1-year suspension. The graph displays positive cash flow for the other current payables and receivables lines, driven by higher advance payments from customers—a practice that carries substantial weight in China—and by tax payables, reflecting other income and greater direct tax expense booked in the period.

Enrico Romagnoli

executive
#12

The company raised capital from employees exercising stock options, which brought in EUR 4 million during the half year and also helped improve the net financial position. Because the year-over-year comparison isn't very meaningful, we also gave the figures for sales and turnover against 2019. In 2021, the medical sector represented roughly 54% of the group <<inaudible>>, and the CAGR for the medical sector across 2019 and 2021 came to 14%. The surge in aesthetics segment sales is a very significant figure, marking the strongest growth rate since 2019 in the medical sector. That rests on solid growth, especially in hair removal and body contouring applications, driven by an offering of innovative systems that can satisfy the needs of a demand which, after the pause caused by the pandemic's first wave, has gradually come back to growth. Lockdown restrictions have not -- have had a more harmful impact on the surgical segment than on the other one, given the difficulties of getting into hospitals and their focus on COVID treatments. We hope to recover over the coming quarters.

Enrico Romagnoli

executive
#13

The physiotherapy recovery is excellent, with Asa supported on a growth path during the past year. After-sales service turnover was also solid. That includes retiring assistance service plus sales of spare parts and consumables. That rebound might have been larger had external production difficulties not constrained us during the first month of the year in sales of optical fibers for urology. Those critical issues are resolved. And by the second quarter already, product volume and turnover were largely satisfactory. For Industrial, this sector posts a CAGR of 29%, above the medical sector, with exceptional performance recorded by the cutting sector, which is running at a very high rate of plus 35%. These are production and sales volume for which production capacity has been readied through important investment now being used increasingly, with a beneficial effect on the income statement as well, thanks to operating leverage. The trend was very positive too for the other main segments, such as marking and laser sources, in rapid recovery from last year. Excuse me. On one concern, the breakdown by area: growth is significant across all geographical areas where the Group operates for the medical and industrial sector.

Enrico Romagnoli

executive
#14

Andrea, please go ahead with the guidance.

Andrea Cangioli

executive
#15

Like we mentioned in the press release, we're revising and enhancing our guidance for 2021. Projected 2021 sales, naturally, assuming nothing material is disrupted by how the pandemic develops and by supply chain strength and shortages as I noted earlier — what I mean is, projected sales ought to surpass EUR 550 million. Fueled by additional revenue growth, EBIT in the second half ought to top the first-half results. That wraps up our presentation at this point. So we can now begin the Q&A session.

Bianca Fersini-Mastelloni

operator
#16

<<operator_script>> Andrea, we have a single question coming from Francois Robillard.

François Robillard

analyst
#17

Starting with the split of second-half growth between your medical and surgical segments — could you give us some color on the growth rates you're anticipating? I notice a few of your U.S.-listed medical laser peers are looking for top line growth of approximately 20% in the second half versus the second half of 2020, which was rather strong. Would you expect the same for your division? And for your Industrial segment, the EUR 67 million of sales since the second quarter — is that your new baseline speed, meaning can we expect a similar amount in the coming quarters as well? Please just comment on that. Then, on your new guidance for the full year '21 EBIT, can you give us some more details on these expectations? I saw that you booked a provision of EUR 2.8 million in the first half. Is that reflected — how do you reflect this in your new guidance? And is it reasonable to expect an EBIT margin of 12%? And last question, going into 2022, do you have any visibility for growth for next year? And can you share with us your expectations?

Andrea Cangioli

executive
#18

Thanks, Francois. Honestly, I can't really respond to any of those questions, since we've issued our guidance and that guidance stands as given. So that's more than EUR 550 million plus better EBIT in the second half. To offer you a bit of the color you were after, what I can say is that demand in Medical and Industrial remains sustained. As a result, we anticipate strong growth across both areas. Right now, I can share that we foresee a relative -- relative, mind you, not absolute -- deceleration in China for industrial laser applications, yet we still anticipate orders growth that ought to let us hit the consolidated targets we referenced. Yes, correct, in first-half EBIT we carried some extraordinary accrual, which likely won't repeat in the second half. That's why we could see EBIT improve, driven not solely by higher revenues but also by the absence of that accrual that we should -- we shouldn't have again, the accruals like the impact we had in the first half.

Andrea Cangioli

executive
#19

What we anticipate is somewhat higher costs, which will therefore create a bit of a hit to EBIT, as we gradually return to congress and fair activity. At the end of this week, the antiaging congress is going to be held in Monte Carlo, Monaco. And for the first time, we'll be able to bring our distributors together in a distributor event, something that hasn't happened over the last 2 years. So we're attending this event in person, and it falls into the category of events that we hold abroad, that are quite expensive, and that have been absent from our activities and from our P&L over the last 18 months. So gradually, they are coming back up. But even so, we can confirm that we expect EBIT in the second half to be higher than in the first half. And since we were above 11%, yes, we hope we can get closer to 12%. But we don't provide any guidance, any detailed guidance, on that number.

François Robillard

analyst
#20

And regarding 2022, are there any initial expectations you could share with us?

Andrea Cangioli

executive
#21

In 2022 — I mean, during my presentation — I somehow brought up how, at this point, we find ourselves well ahead on the growth path that we're on. If I look at where we stand now, in order, I believe I can say that we're in a very solid position, a very solid position. And that part of our backlog will probably shift into 2022, because we ask customers to plan their deliveries so they can set up the right production capacity and meet their requests. So right now, what we're seeing is a strong second half of 2021, with good momentum carrying into 2022. But I'm not telling you anything new. Ours is a market where orders aren't placed with financial collateral. We saw back in 2020 how quickly our huge backlog was essentially canceled by our customers. That's why — even though we're extremely confident — it isn't on an order book that we piled up today that we can count for 2022. What we can count on for 2022 is the strength of the market, the good conditions of the market, and the good positioning that we still have, and that we have today.

Andrea Cangioli

executive
#22

That's why, when it comes to 2022, my main thought is that we're quite optimistic about what's achievable in 2022 given what we know right now. Still, we're making no commitments and offering no promises today — as always, we aim to stay very prudent, given how our markets and our demand behave.

Bianca Fersini-Mastelloni

operator
#23

Okay, Andrea — we've got a question coming in from Andrea Bonfa over at Banca Akros.

Andrea Bonfà

analyst
#24

Alright, at the moment I basically have 2 questions. The first concerns how the Industrial segment did in the second quarter. Italy and Europe appear to have done very well and even accelerated compared with Q1. So is this again a trend you are seeing? What is your view on that particular geographic performance? If you could comment on it. And second, if you like, this is a provocative question: you mention that you are going back to spending on congresses and probably marketing. But you are growing at 70% year-on-year, or 60% if you look at H1 '19. And the question is, do you need these kinds of expenses, because you are doing so well without them, so maybe they are not so necessary. Again, I understand it is a provocative question. And of course, you need to have some marketing activities, but I would like to hear your opinion on the future budget for these kinds of expenses.

Andrea Cangioli

executive
#25

Thanks for those questions, Andrea. Beginning with Italy on the industrial side, things are going very well indeed. In my view, our Italian plant had an extremely solid strategy and is very well positioned, and the outstanding Q2 2021 results show just how forcefully we went after the market and how we are picking up share against competitors that are stronger and bigger than us. The trend right now remains very positive as well. As I said in my first answer too, we anticipate that in the second half of 2021 the Italian business will outperform the Chinese business, relatively speaking, of course. We have been very aggressive indeed. Our products perform at a high level. We sell them at a price that, naturally, is not especially lucrative for us, though it does carry a healthy industrial profit, and that lets us earn solid profits on one hand while also growing our share quickly, strengthening our market position quickly, and gaining better visibility in the market. And this is building through a virtual process that is turning our Cutlite Penta into a highly successful company during these months, in this quarter.

Andrea Cangioli

executive
#26

Yeah. That's a good question, and it's a really good one about marketing expense. We're always thinking about this, because this month, of course, we're seeing a very positive situation where we have a large quantity of orders, but we aren't spending the amount of money we used to spend to generate those orders. So, I mean, logic would say, well, we have all these orders, so why are you spending money? Why do you keep spending money? I believe there was an overshoot in expenditure that ended with the pandemic. So in 2018, we were spending — I mean, the marginal benefit of the money spent on marketing was getting quite low. Now there has been an overshoot due to the pandemic, during which we couldn't do any international marketing activities. I believe that since we're in a competitive market, since marketing and market activity presence is part of the margin mix, I believe all the companies will go back to some marketing presence. All the companies will start attending the main congresses. Probably, there will be less attendance at the second body of conferences, and there will be less travel.

Andrea Cangioli

executive
#27

Incidentally, in this instance, unfortunately, no money is being spent by us, since these congresses are among the various activities for which a ticket was provided when the initial congresses got canceled. So if we don't attend -- if we didn't attend on this occasion, the down payment we made at this point 2 years ago will be lost. So no additional expense is being created by us through participating in this progress, because if you wouldn't participate, everything would have been lost by us, down payments the hotel's down payments to the fair organization. But regarding what I believe is going to go on in the next years, a slower return to the expenditure is what I believe there will be. And I believe that finally, lower in expense than we were at the end of 2019 is where we will remain.

Bianca Fersini-Mastelloni

operator
#28

Andrea, there’s one additional question coming from Andrea Randone at Intermonte.

Andrea Randone

analyst
#29

I’ve got a couple of questions, if that’s all right. First, regarding your aesthetic business: you’ve already talked about the top-performing applications. I’m curious whether you could add some comments on geographical trends. And more broadly, how do you see your customers’ business results in this segment? Second, on your production capacity and, more generally, your future CapEx plans, could you give us an update?

Andrea Cangioli

executive
#30

Were you referring to customers or competitors?

Andrea Randone

analyst
#31

What I was getting at with customers is figuring out whether things are going really well for them — whether they're picking up new applications, new machinery, and so on. For example, we discussed people returning to gyms and requesting new equipment for that restart. And I'm curious whether something comparable is happening at aesthetic centers, or what you're seeing in terms of business trends for your customers?

Andrea Cangioli

executive
#32

Yes. Yes. I think you raised a valid point. Right now our customers are operating at full review. They're up against very strong demand. And that's what's driving a very strong demand for systems on our side. People have been ready to put money into aesthetic treatments. That's been a psychological effect following the lockdowns. It's also been an effect of disposable income, given that not many leisure expenditures have been permitted. But the bottom line is that demand has grown. And we were positioned so that we could meet a high and rising level of demand. The areas — geographic areas — where we've had particular success are, in the first place, the United States. In the United States, we're seeing great success in aesthetic through 2 distribution channels. One is the distributor for aesthetic application for DEKA, the DEKA brand. And for the Quanta brand, which is part of Asa, and the other one is our long-term partner Cynosure, which sells our hair removal laser in the U.S. and worldwide as well. We've also been extremely pleased about the success of our professional statics market in Italy and in Japan.

Andrea Cangioli

executive
#33

This is not a medical aesthetics look — it's a spa and salon aesthetic, and it has done extremely well in Italy, Japan, and Germany as well. On production capacity, you're correct. We've been putting money into capacity for years, yet volume growth has stayed steady over those years. So we need to keep investing so that our production capacity rises further. As for industrial laser applications, we're constructing new plants during 2021 in Leni and in Wenzhou, and that takes us to 5 facilities in total. At some point in 2022, we may also expand our site in Wuhan. Right now we don't own a facility there — we lease it — but given the chance to get substantial backing from local authorities, we might also look at growing Wuhan's production capacity further. On the medical business side of capacity, we've just wrapped up a series of expansions at the companies in Germany, at Quanta System, and at Asa. And there's sufficient room for us to add capacity without any major infrastructure spending. Still, if demand stays as robust as it has been in recent months, we'll have to redesign some products on the line, and not just through adding capacity of our own — we'll also enable our partners to add capacity together with us.

Andrea Cangioli

executive
#34

Just remember that we don’t handle the entire production cycle for every one of our products. For a number of products, though, we rely on third parties that carry out part of that production cycle. As a result, we’ll need to strengthen the network of third parties doing some of the manufacturing work for us. I don’t view that as a major problem. We’ve done it before, and El.En’s growth has also meant growth for our partners in recent years.

Bianca Fersini-Mastelloni

operator
#35

Andrea, no further questions have come in, so let me check with the investors whether anyone else has something to ask. Any more questions?

François Robillard

analyst
#36

Sure, Bianca — I'd like to add one more question, if I can. On the gross margin side: H1 '21 showed a good recovery compared with the second half of '20, when medical ran into some issues. Even so, you remain under where you stood in H1 '19. Does that mirror today's inflationary conditions? Or what explains why your gross margin can't get back to the H1 '19 level, let's say?

Andrea Cangioli

executive
#37

It comes down to a question of mix. And that applies inside each sector as well. Take the industrial sector: China's share and sheet metal's share have both kept getting bigger. So we understand that growing in that market means operating on thinner margins. In this segment, then, we are expanding, but margins have stayed broadly stable, with a bigger proportion coming from lower-margin sales. To some degree we have to accept this, since raising margins is extremely hard in the highly competitive markets where we operate. Beyond that, keeping margins low was a strategic choice, made to win market share and to turn into an entity with respectable revenue. Keep in mind that in sheet metal cutting, the big rivals are competitors on the scale of EUR 1 million, by strong, EUR 2 million and change plans, EUR 2 million — sorry, EUR 1 million all in our segment has lifted. So we must build up dimension so we can keep competing against those drivers. As for medical, that too is a matter of mix.

Andrea Cangioli

executive
#38

And naturally, we should also take into account that this big jump in revenue stems partly from growth in the hair removal market, which happens to be the most standardized among these markets — high volumes, yes, but we do have to give up some margin. Looking back at 2019, there was more space for products that had just been launched — newly released items — which carry very high margins today. The prevalence of hair removal, and of certain customers with whom we generate volume, does not deliver very high margins — Cynosure customers, as we mentioned earlier, are an example — but it lets us run a bigger business and achieve a higher gross margin in euro terms, though it does not let us expand margin on sales as a percentage. From that standpoint, I don't expect major shifts as we move through this year, because structurally we will have roughly — let's say — the same type of revenue, the same kind of revenue. What is improving, it is improving right now. The euro-U.S. dollar exchange rate is stronger at present than it was at the start of the year. That is why we will capture more margin in the last — in the fairly large sales volumes we have to the United States.

Andrea Cangioli

executive
#39

And then last but not least, we haven't yet seen a real effect from the cost increases we had. But — and so, today, we're keeping prices and margins more or less the same, because even though we see cost increases in several components, those aren't material to the total effect of our, let's say, bills of materials. There's a question mark here on how the raw material cost increase will impact on the midterm. The good news here is that they'll impact our cost as much as they'll impact the cost of our competitors. Therefore, it will be for — in order to maintain margins, to slightly increase prices between this at which all of our competitors will be exposed.

Andrea Randone

analyst
#40

Only 2 quick follow-ups. But suppose Italy and Europe in industrial end up doing better than China, and urology in America gets back to growing, would gross margin normally improve?

Andrea Cangioli

executive
#41

Correct.

Enrico Romagnoli

executive
#42

Correct.

Andrea Cangioli

executive
#43

Sure — assuming those 2 things, and going off the 2 assumptions you just laid out, that effect ought to show up.

Bianca Fersini-Mastelloni

operator
#44

Andrea, there's one more question coming from Francois at Intermonte.

François Robillard

analyst
#45

Just a quick question about Slide 7 and the working capital pieces. I mean, trade working capital had a negative effect on your cash flow during this first half, though you saw some positive effects from other receivables and payables. Should we expect that positive effect from the first half to reverse in the second half? And the same question applies to the trade working capital components.

Andrea Cangioli

executive
#46

Regarding your first question — whether that effect might reverse — my view is no, I don't think so. I really don't. Even so, keep in mind that these other receivables and payables, or short-term payables, are driven largely by 2 elements. The first is customer down payments. The second is short-term liabilities tied to income taxes. So, as I'm indicating to you that income will rise, or at least we hope it rises, in the second half, the short-term tax liability ought not to be coming down. As for customer down payments, that hinges on the balance — on total backlog. Normally, a larger backlog translates into a larger payable versus customers for down payments. Therefore, should the trends keep climbing and should we keep holding the backlog we have today, we won't witness any reduction in payables to customers for down payments. Naturally, at the point when we do see a reduction in the payable to customers for down payments, those down payments will have been converted into sales. So revenues will be higher, but there will also have been a slowdown in order bookings. That could indeed happen. Yet at the same time, we should likewise see net working capital come down, or at minimum the inventory portions of net working capital, since what customer down payments are typically used for is covering the inventory increase required to deliver the units to customers.

Bianca Fersini-Mastelloni

operator
#47

Andrea, there’s another question coming in from Katharina Raatz at Berenberg.

Katharina Raatz

analyst
#48

I'd appreciate getting a clearer picture of the market conditions you're seeing right now in China. To start with, some additional context would be great. Specifically, what did China contribute in terms of growth during H1? And how has the market environment evolved as well? It's useful that you've already gone into some detail about possible capacity expansion as we head into next year, along with the level of competition or share gains relative to peers, but more specifics on China would be very helpful to me.

Andrea Cangioli

executive
#49

Right, so the thing is they contributed quite nicely to what we delivered in the first half. Enrico can walk you through how sales grew by geography. If you look at that column showing EUR 81.3 million for the rest of the world — that's mostly China, essentially our Chinese operations — you'll see they posted solid growth. Sure, it wasn't as rapid as what we saw in Italy, which was 44%. But when you factor in the size of that company, averaging 24% growth across 2 years is a remarkable — a remarkable outcome. What we've seen during the final months of this 2021, through the summer, is that incoming orders decelerated somewhat during the early summer months, which is a pattern that has always occurred apart from last year. Normally, order books ease off in the summer. That didn't happen in 2020, though there were clear reasons why it didn't happen in 2020, since in 2020 we were emerging from the lockdown. As a result, order bookings rose steadily from spring through summer and on into the fall.

Andrea Cangioli

executive
#50

The outlook we have — and what we're seeing from competitors as of September 13 — is that we're heading into a full season, and it looks set to be a good one. Following that slight slowdown, we anticipate sales climbing steadily as the year draws to a close, and we're counting on a solid 2022. Broadly speaking, we're operating at high speed, at very high speed. Across the whole economy during this summer month, overall demand has been somewhat softer than what we saw in the spring months. We'll need to wait a few months before we know. There's this slowdown effect which, based on what we can observe in early September, has already ended, will persist over time, or — as we expect — the momentum of the Chinese economy in our segment will stay very strong through the coming months.

Bianca Fersini-Mastelloni

operator
#51

Any other questions? If there are none remaining, we’ll bring this conference to a close. Should you have any questions you’d like to look into, please feel free to reach out to Enrico Romagnoli. He’ll be glad to answer them. Thanks for joining this conference, and we hope to see all of you at the next occasion. Good afternoon to everyone.

Andrea Cangioli

executive
#52

Thanks, everyone. Take care.

Enrico Romagnoli

executive
#53

<<foreign_lang>> Goodbye.

Bianca Fersini-Mastelloni

operator
#54

Take care.

Andrea Cangioli

executive
#55

And if you have any additional questions, feel free to reach out to us—we're always somewhat available to provide explanations for all of you. Thank you, Bianca. Thank you, Enrico. Bye-bye.

Bianca Fersini-Mastelloni

operator
#56

<<foreign_lang>> Farewell.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.